Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
Date:3/5/2009

--------------- ------------------------------------------------------------------------- Weighted average shares outstanding (000's) - basic and diluted 85,015 85,015 ------------------------------------------------------------------------- ------------------------------------------------------------------------- a. Amounts accrued for costs incurred, and potential future costs, related to our offer to accept returns of Contour Threads brand product as part of consolidation and discontinuation of the Contour Threads brand name, coincident with the launch of our Quill SRS brand name. b. Non-recurring, non-operating license revenue. c. Severances and reorganization costs. In 2007, change in estimate of accounting for excess and obsolete inventory resulting from the alignment during the second quarter of 2007 of inventory policies across our various manufacturing operations. d. Research and development adjustments: --------------------------------------------------------------------- Year-ended Year-ended Dec 31, 2008 Dec 31, 2007 ------------- ------------- Stock-based compensation (795) (1,665) License fees due to licensors related to non-recurring license revenue - (419) Termination and reorganization costs (3,302) (849) Non-recurring supply / distribution agreement termination costs (500) (899) Non-recurring research and development expenses and intellectual property license agreement. (938) (750)
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/29/2015)... , July 30, 2015 ... results for the second quarter of 2015. CEO ... results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered ... results - Performance drivers ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... the Company,s Chief Financial Officer has resigned.  The Company ... Financial Officer who retired in December 2014, as full ... a permanent successor.     Andy Ashworth ... and ensure a smooth transition.  Andy was the Company,s ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... Physicists at the University of California, Berkeley, have built the ... the diameter of a human hair that requires only a ... , The scientists successfully received their first FM broadcast last ... Boys, "Good Vibrations" transmitted from across the room. In homage ...
... 31 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc.,(TSX: DDD; ... its biotech method,for 7ACA production has been ... believes this achievement validates the Company,s research,and ... This,technology would bring immediate benefits to production ...
... CRANBURY, N.J., Oct. 31 Amicus Therapeutics,(Nasdaq: ... small molecule,orally-active pharmacological chaperones for the treatment ... for the third quarter of 2007.,On a ... Generally Accepted,Accounting Principles (GAAP), Amicus announced a ...
Cached Biology Technology:World's smallest radio uses single nanotube to pick up good vibrations 2World's smallest radio uses single nanotube to pick up good vibrations 3World's smallest radio uses single nanotube to pick up good vibrations 4Dragon Announces R&D Achievement in Biotech Manufacturing Process 2Dragon Announces R&D Achievement in Biotech Manufacturing Process 3Amicus Therapeutics Announces Third Quarter 2007 Financial Results 2Amicus Therapeutics Announces Third Quarter 2007 Financial Results 3Amicus Therapeutics Announces Third Quarter 2007 Financial Results 4Amicus Therapeutics Announces Third Quarter 2007 Financial Results 5Amicus Therapeutics Announces Third Quarter 2007 Financial Results 6Amicus Therapeutics Announces Third Quarter 2007 Financial Results 7Amicus Therapeutics Announces Third Quarter 2007 Financial Results 8
(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
(Date:7/13/2015)... 13, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND ... and secure method to make payments.  With this ... introduced with its groundbreaking voice-direct payment patent application, ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... the University of Leeds, UK, the Charit University Medical ... Medicine (MDC) in Berlin, Germany, have discovered a new ... identified how ,junk, DNA promotes the growth of cancer ... (University of Leeds) and Dr Stephan Mathas (Charit, MDC) ...
... estimated that nearly 1.5 million Americans have been diagnosed with ... are believed to have some form of autism, according to ... and Prevention (CDC). Find out what new research and treatment ... ASD seen over the past few decades at a panel ...
... Heart and liver transplant recipients are at particularly ... donated organ, researchers report at the 2nd European Lung ... such cancers in these patients to maximize the chance ... for decades that the immunosuppressive drugs given to transplant ...
Cached Biology News:'Junk DNA' drives cancer growth 2Expert panel to discuss autism spectrum disorders 2Lung cancer risk particularly high for heart and liver transplant recipients 2
... PHD2000 syringe pump series combines Harvard Apparatuss best ... and a wide range of configuration options. A ... dimensions of syringes from all the major manufacturers. ... all the pertinent information from across the lab. ...
Mouse monoclonal antibody to RAD51L3 - RAD51-like 3 (S. cerevisiae)...
... you to store and manage very large ... secure central relational database. Storing and managing ... resource for clone tracking and enables you ... analysis. LabShare software integrates seamlessly with Invitrogen's ...
... A and Protein G bind specifically to ... A and Protein G conjugates are commonly ... (antibodies) and immunoglobulin subtypes from serum, hybridoma ... biological fluids. These reagents are also commonly ...
Biology Products: